RxDoctor Payments Data

Margaret Socha, NP

Adult Health · Clifton Springs, NYNPI 1205355229

Payments from drug & device makers

$1,321in general payments, 2019–2025

Across 83 payments — averaging $15.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$762
  • Abbott$87
  • Novartis$73
  • Novo Nordisk$71
  • Insulet Corporation$62
  • Bayer$60
  • plus $206 from 6 others

What the payments were for

  • Food & beverage$1,321100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,321 in reported general payments places this provider in the 70th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$7,563
Medicare patients
83
Services billed
119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide74$96,390
MounjaroTirzepatide78$91,108
OzempicSemaglutide71$81,046
JardianceEmpagliflozin50$57,722
Humulin R U-500 KwikpenInsulin Regular, Human22$33,705
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog42$22,872
JanuviaSitagliptin Phosphate20$22,543
Lantus SolostarInsulin Glargine,hum.Rec.Anlog105$18,868
FarxigaDapagliflozin Propanediol16$17,593
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/714$16,645
Insulin Lispro Kwikpen U-100Insulin Lispro47$14,824
Novolog FlexpenInsulin Aspart18$4,483
Nano 2nd Gen Pen NeedlePen Needle, Diabetic45$3,964
Levothyroxine Sodium112$1,684
Glimepiride90$1,531

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$762$187,498152 claims
Novo NordiskOzempic$71$81,04671 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,828 adult health providers in New York.

Other adult health in Clifton Springs

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →